Diabetes Cae Beyond Metes and Stips R&D Day, May 2004 Staffan Ek Head of Diabetes Cae, Roche Diagnostics 1 Roche is well positioned in gowing maket segments Blood Glucose Monitoing maket size 7.3 bn CHF (2003) CAGR 04-09 7 % Insulin Infusion Systems maket size 640 mchf (2003) CAGR 04-09 15 % 38 % 26 % 62 % Roche Competitos 74 % Roche Competitos Souce: Roche analysis 2 Roche R&D Day 2004/Ek Diabetes Cae 1
Stategy focused on thee coe poduct aeas To enable people with diabetes and HCPs to manage diabetes cae by poviding pioneeing individualized tools, poducts and solutions, that allow fo actionable outcomes Connectivity solutions/ infomation management Innovative Blood Glucose Monitoing Systems Mete-Stip Systems Integated Systems Continuous Glucose Monitoing Systems Insulin Pump Systems New Business Initiatives 3 Two technological appoaches Integated Blood Glucose Monitoing educing numbe of devices (combining into one catidge) Compact I II multiple stips/ continuous stip 1 2 illustative educing numbe of steps (consolidation of lancet, capillay action and measuing) 4 Roche R&D Day 2004/Ek Diabetes Cae 2
Two technological appoaches Benefits Roche benefits Reinfoces innovative eputation Stengthens #1 maket position Lowe manufactuing costs Sales of ove 1 bn CHF p.a. expected 4 yeas afte launch Custome benefits No stip handling Impoved hygiene Less pain no blood seen Small, fully integated slim device A. Reducing # devices B. Reducing # steps Continuous Stip Lancing Stip Measuing Needle 5 Continuous Glucose Monitoing Roche pusuing two technologies mico dialysis needle-type senso Unique viscometic measuement pinciple Povides supeio accuacy Clinical tial GlucOnline in Q3 04 Electo-chemical senso technology Reduced size and weight Potentially impotant fo use in continuous monitoing & automated panceas Leveaging technologies fom the Roche goup Disetonic, Bugdof Roche Nea Patient Testing, Gaz Roche Diabetes Cae, Mannheim and Indianapolis 6 Roche R&D Day 2004/Ek Diabetes Cae 3
Infusion Systems: new poducts launched Business and development pogams defined Disetonic integation finished development pogams defined TÜV quality system inspection successfully passed Pepaation fo FDA e-audit pogessing well Potfolio steamlined Development and technology pojects defined new poduct launched next steps in pepaation Pilot launch Apil 04 in The Nethelands 7 Fom bg monitoing to diabetes management An integated solution in potfolio Roche popietay IR communication Compact Pocket Compass Pump histoy data Bolus Rec Tool Hot Sync USB / RS 232 DiaLog / DiaLog Po DMS popietay IR communication SmatPinte Sensotend Low Powe RF Camit Po Pocket Remote Contol Watch Remote Contol 8 Roche R&D Day 2004/Ek Diabetes Cae 4
Roche Diabetes Cae: well positioned to futhe dive the value of the band Good stating position Sustained high single digit maket gowth Maket leade in Blood Glucose Monitoing and No. 2 in Infusion Systems Integated Systems well accepted by maket and excellent pospects Balanced potfolio and investment ensue boad options Next geneation of integated systems in development New infusion pump on the maket Connectivity and infomation management build the backet aound the potfolio offes moe than a poduct offes a potfolio of custome focused solutions! 9 Appendix 10 Roche R&D Day 2004/Ek Diabetes Cae 5
Substantial Potfolio keeps Roche Diabetes Cae ahead of the maket bg Monitoing Insulin Delivey D-TRON D-TRONplus D-TRONplus update Infom Supe Fast Compact Test Stip Advantage Advantage (III) Active H-TRON Active (new) Infom LCM Compact (II) New pump Compact LCM & Integated System Continuous Glucose Monitoing Infom II Advantage Successo Go Go (new) 2002 2003 2004 onwads 11 Roche R&D Day 2004/Ek Diabetes Cae 6